2016

NOTICE OF
ANNUAL
SHAREHOLDERS’
MEETING
Notice is hereby given that the Annual Shareholders’ Meeting will be held at the Guineas Ballroom, Ellerslie Event Centre, Auckland, New Zealand on Tuesday, 23 August 2016 commencing at 2:00pm (NZST).

HOW TO GET TO THE ELLERSLIE EVENT CENTRE
BUSINESS

A CHAIRMAN’S ADDRESS

B MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER’S REVIEW

C FINANCIAL STATEMENTS

To receive and consider the financial statements and the auditors’ report for the year ended 31 March 2016 as contained in the Company’s 2016 annual report.

D RESOLUTIONS

To consider, and if thought fit, to pass, the following ordinary resolutions:

(1) **Re-Election Of Director**
That Michael Daniell, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company.
*(See Explanatory Note 1)*

(2) **Re-Election Of Director**
That Donal O’Dwyer, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company.
*(See Explanatory Note 2)*

(3) **Election Of Director**
That Lewis Gradon, who, being eligible, offers himself for election, be appointed as a director of the Company.
*(See Explanatory Note 3)*

(4) **Election Of Director**
That Scott St John, who, being eligible, offers himself for election, be appointed as a director of the Company.
*(See Explanatory Note 4)*

(5) **Auditor’s Remuneration**
That the Directors be authorised to fix the fees and expenses of PricewaterhouseCoopers as the Company’s auditor.
*(See Explanatory Note 5)*
(6) Fisher & Paykel Healthcare Performance Share Rights Plan – Issue of performance share rights to the Managing Director and Chief Executive Officer

That approval be given for the issue of up to 50,000 performance share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan to Mr Lewis Gradon, Managing Director and Chief Executive Officer of the Company.

(See Explanatory Note 6)

(7) Fisher & Paykel Healthcare 2003 Share Option Plan – Issue of options to the Managing Director and Chief Executive Officer

That approval be given for the issue of up to 120,000 options under the Fisher & Paykel Healthcare 2003 Share Option Plan to Mr Lewis Gradon, Managing Director and Chief Executive Officer of the Company.

(See Explanatory Note 7)

PROCEDURAL NOTES

(i) The persons who will be entitled to vote on the resolutions at the Annual Shareholders’ Meeting are those persons who will be the shareholders of the Company at 5:00pm on Wednesday, 17 August 2016 (NZST).

(ii) A shareholder may exercise the right to vote at the Annual Shareholders’ Meeting either by being present in person or by proxy. A body corporate who is a shareholder may appoint a representative to attend the Annual Shareholders’ Meeting on its behalf in the same manner as that in which it could appoint a proxy.

(iii) A proxy need not be a shareholder of the Company. A shareholder who wishes to do so may appoint the Chairman of the Meeting to act as proxy.

(iv) A proxy will vote as directed in the proxy form or, if voting is left to the proxy’s discretion, then the proxy will decide how to vote on the resolutions. If the Chairman is appointed as proxy and the voting is left to his discretion, the Chairman intends to vote in favour of each of Resolutions (1) to (7).

(v) A proxy form is enclosed and, if used, must be lodged with the share registrar, Link Market Services Limited, in accordance with the instructions set out on the form not less than 48 hours before the time of the holding of the meeting (i.e. before 2.00pm on Sunday 21 August 2016 (NZST)).

(vi) The Company will disregard any votes cast on Resolutions (6) and (7) by Lewis Gradon and any of his associates (as defined in the Australian Corporations Act 2001).
(vii) The Company need not disregard a vote cast on Resolutions (6) or (7) if it is cast by a disqualified person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form.

(viii) Resolutions (1) to (7) must be passed by an ordinary resolution of shareholders, i.e., by a simple majority of the votes of those shareholders entitled to vote and voting on the resolution in person or by proxy.

(ix) This Notice of Meeting has been approved by NZX Limited (NZX) in accordance with NZX Main Board Listing Rule 6.1.1. The NZX does not take any responsibility for any statement in this notice.

Explanatory Notes
Explanatory notes in respect of the resolutions are set out on the following pages.

By Order of the Board of Directors

______________________________

TONY CARTER
Chairman
8 July 2016
EXPLANATORY NOTE 1 – RE-ELECTION OF DIRECTOR

Under Listing Rule 3.3.11 of the NZX Main Board Listing Rules, and in accordance with the Company’s constitution, one third of the Company’s Directors (excluding any Directors appointed by the Board under Listing Rule 3.3.6 of the NZX Main Board Listing Rules) must retire by rotation at the Annual Shareholders’ Meeting. If the Directors are eligible, they may offer themselves for re-election by shareholders at the meeting. In this case, Michael Daniell retires by rotation and, being eligible, offers himself for re-election by shareholders at the Annual Shareholders’ Meeting.

Michael Daniell previously served as the Company’s Chief Executive Officer and Managing Director and with effect from 1 April 2016 Mr Daniell moved into the role of a non-executive Director. Due to his transition from the role of Chief Executive Officer and Managing Director, Mr Daniell is not considered by the Board to be an Independent Director, as that capacity is described in the NZX Main Board Listing Rules. A brief biography outlining Mr Daniell’s qualifications, history and experience is set out below. At the Annual Shareholders’ Meeting a resolution to re-elect Mr Daniell will be put to shareholders.

The Board recommends that shareholders vote in favour of the re-election of Michael Daniell. Mr Daniell abstained from any consideration by the Board on his re-election.

Michael Daniell

Michael Daniell became a non-executive Director in April 2016. He was formerly Managing Director and Chief Executive Officer of Fisher & Paykel Healthcare from November 2001 to March 2016. He was General Manager of Fisher & Paykel’s medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mike is a member of the Council and Chair of the Finance Committee of the University of Auckland, a director of Tait Limited and Chair of the Medical Technologies Centre of Research Excellence. He holds a Bachelor of Engineering degree in electrical engineering from the University of Auckland, New Zealand.
EXPLANATORY NOTE 2 – RE-ELECTION OF DIRECTOR

Under Listing Rule 3.3.11 of the NZX Main Board Listing Rules, and in accordance with the Company’s constitution, one third of the Company’s Directors (excluding any Directors appointed by the Board under Listing Rule 3.3.6 of the NZX Main Board Listing Rules) must retire by rotation at the Annual Shareholders’ Meeting. If the Directors are eligible, they may offer themselves for re-election by shareholders at the meeting. In this case, Donal O’Dwyer retires by rotation and, being eligible, offers himself for re-election by shareholders at the Annual Shareholders’ Meeting.

Donal O’Dwyer is a non-executive Director and is considered by the Board to be an Independent Director, as that capacity is described in the NZX Main Board Listing Rules. A brief biography outlining Mr O’Dwyer’s qualifications, history and experience is set out below. At the Annual Shareholders’ Meeting a resolution to re-elect Mr O’Dwyer’s will be put to shareholders.

The Board recommends that shareholders vote in favour of the re-election of Donal O’Dwyer. Mr O’Dwyer abstained from any consideration by the Board on his re-election.

Donal O’Dwyer

Donal O’Dwyer became a Director in December 2012. Mr O’Dwyer is Chairman of Atcor Medical Pty Limited and a non-executive director of Cochlear Limited, Mesoblast Limited and nib Holdings Limited. From 1996 to 2003, Mr O’Dwyer worked for Cordis Cardiology, the cardiology division of Johnson & Johnson’s Cordis Corporation, initially as its president (Europe) and from 2000 to 2003 as its worldwide president. Prior to joining Cordis, Mr O’Dwyer worked for 12 years with Baxter Healthcare, rising from plant manager in Ireland to president of the Cardiovascular Group, Europe, now Edwards Lifesciences. Mr O’Dwyer is resident in Australia, is a qualified civil engineer and has an MBA.

EXPLANATORY NOTE 3 – ELECTION OF DIRECTOR

Under NZX Main Board Listing Rule 3.3.6 and in accordance with the Company’s constitution, any Director appointed by the Board must retire from office at the next Annual Shareholders’ Meeting of the Company but is eligible for election at that meeting.

On 31 March 2016, Lewis Gradon was appointed by the Board as Managing Director of the Company with effect from 1 April 2016. Accordingly, Mr Gradon retires and, being eligible, offers himself for election by shareholders at the Annual Shareholders’ Meeting.
Lewis Gradon is an executive Director and is not considered by the Board to be an Independent Director, as that capacity is described in the NZX Main Board Listing Rules. A brief biography outlining Mr Gradon’s qualifications, history and experience is set out below.

At the Annual Shareholders’ Meeting a resolution to elect Mr Gradon will be put to shareholders. The Board recommends that shareholders vote in favour of the election of Mr Gradon. Mr Gradon abstained from any consideration by the Board on his election. If Mr Gradon is elected as a Director at the Annual Shareholders’ Meeting, his term of appointment as a Director shall not exceed five years (being the maximum period permitted by the NZX Main Board Listing Rules), during which time he will be exempt from the obligation to retire by rotation pursuant to NZX Main Board Listing Rule 3.3.12 and the Company’s constitution. Following this five year period Mr Gradon will be eligible for re-election as a Director.

Lewis Gradon
Prior to being appointed the Chief Executive Officer and Managing Director in April 2016, Lewis Gradon served 15 years as Senior Vice President - Products & Technology, and six years as General Manager – Research and Development. During his 33 year tenure with Fisher & Paykel Healthcare he has held various engineering positions and overseen the development of our complete healthcare product range. Lewis holds a Bachelor of Science in Physics from the University of Auckland, New Zealand.

EXPLANATORY NOTE 4 – ELECTION OF DIRECTOR

Under NZX Main Board Listing Rule 3.3.6 and in accordance with the Company’s constitution, any Director appointed by the Board must retire from office at the next Annual Shareholders’ Meeting of the Company but is eligible for election at that meeting.

On 11 September 2015, Scott St John was appointed by the Board as a Director of the Company with effect from 1 October 2015. Accordingly, Mr St John retires and, being eligible, offers himself for election by shareholders at the Annual Shareholders’ Meeting.

Scott St John is a non-executive Director and is considered by the Board to be an Independent Director, as that capacity is described in the NZX Main Board Listing Rules. A brief biography outlining Mr St John’s qualifications, history and experience is set out below.

At the Annual Shareholders’ Meeting a resolution to elect Mr St John will be put to shareholders. The Board recommends that shareholders vote in favour of the re-election of Scott St John. Mr St John abstained from any consideration by the Board on his re-election.
Scott St John

Mr St John was appointed Chief Executive Officer of First NZ Capital in 2002. He joined First NZ Capital’s predecessor company CS First Boston in 1993 following seven years at Hendry Hay McIntosh. Mr St John is a member of Chartered Accountants Australia and New Zealand and a member of the Institute of Finance Professionals of New Zealand. He is Pro Chancellor of the University of Auckland, where he has also Chaired the Finance Committee. Mr St John received his Bachelor of Commerce degree and Diploma in Business from the University of Auckland.

EXPLANATORY NOTE 5 – AUDITOR’S REMUNERATION

PricewaterhouseCoopers is automatically reappointed as the auditor of the Company under section 207T of the Companies Act 1993. This resolution authorises the Board to fix the fees and expenses of the auditor in accordance with section 207S of the Companies Act 1993.

As foreshadowed at last year’s Annual Shareholders’ Meeting, the Company has commenced a competitive process for the provision of external audit services to the Company and its subsidiaries. Our current auditor, PricewaterhouseCoopers, has been invited to participate in that process. The Company expects to be able to announce the outcome of the process on or about the date of the Annual Shareholders’ Meeting. If PricewaterhouseCoopers is successful, it will continue as auditor. If another audit firm is selected, PricewaterhouseCoopers will continue as auditor until the appointment process is complete, which would be expected to occur during the final quarter of calendar year 2016, at which point the appointment of the new auditor would become effective.

EXPLANATORY NOTE 6 – FISHER & PAYKEL HEALTHCARE PERFORMANCE SHARE RIGHTS PLAN – ISSUE OF PERFORMANCE SHARE RIGHTS TO THE MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

Introduction

The Company’s remuneration arrangements for senior executives include the issue of options under the Fisher & Paykel Healthcare 2003 Share Option Plan (the Option Plan) and the issue of performance share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan (the Share Rights Plan). Under the Option Plan, options will vest depending on share price performance relative to a costs of capital benchmark whereas
under the Share Rights Plan, share rights vest depending on the achievement of a designated total shareholder return hurdle. The Board approved the establishment of the Share Rights Plan in accordance with the Share Rights Plan rules dated 16 July 2012. The Board believes that the issue of a combination of options and share rights broadly in equal value proportions will provide appropriate alignment of participating employees to grow the total shareholder return of the Company. The combination of the Option Plan and the Share Rights Plan will also assist the Company to attract, motivate and retain key employees in an environment where such employees are in high demand both within New Zealand and internationally. Options and share rights will be issued to employees under the Option Plan and Share Rights Plan as a long-term component of remuneration provided to employees in accordance with the Company’s remuneration policy, a summary of which is available on the Company’s website at www.fphcare.co.nz/investor/corporate-governance/corporate-governance-policy.

Under the Share Rights Plan, the Board may issue share rights to executives, managers and other employees of the Company and its subsidiaries (or a person associated with them). Share rights do not carry any entitlement to dividends, or the right to vote, prior to exercise. On exercise, a participant will receive one fully paid ordinary share in the Company for each share right exercised. The number of share rights which a participant in the Share Rights Plan will be entitled to exercise will depend on the number of share rights held by the participant and the performance of the Company relative to a designated performance hurdle. Each share right will be issued, and (if exercisable) may be exercised, at no cost to the participant. Further details of the share rights and the Share Rights Plan are described below under the heading “Key Terms of the Share Rights Plan”.

At last year’s Annual Shareholders’ Meeting, approval was obtained to issue 50,000 share rights to Michael Daniell (who was the Managing Director and Chief Executive Officer at the time of issue) and it was indicated that up to 650,000 share rights could be issued to other executives, managers and employees. The actual number of share rights issued to Mr Daniell was 30,000, and 448,350 share rights were issued to other executives, managers and employees. This year, shareholder approval is being sought for the issue of up to 50,000 share rights under the Share Rights Plan to Lewis Gradon, the Managing Director and Chief Executive Officer of the Company. The Company also intends to issue, pursuant to NZX Main Board Listing Rule 7.3.6, up to 650,000 share rights under the Share Rights Plan to selected executives, managers and other employees of the Company and its subsidiaries (or a person associated with them) which will be issued within 5 months of the Annual Shareholders’ Meeting. Together with the options proposed to be issued under the Fisher & Paykel Healthcare 2003 Share Option
Plan (see Explanatory Note 7), the Company intends to issue no more than an aggregate of 2,300,000 share rights and options to selected executives, managers and other employees, including Mr Gradon, following the Annual Shareholders’ Meeting. This will equate to the issue of share rights and options to acquire shares representing approximately 0.4% of the total ordinary shares on issue; if all of these share rights and options were exercised for shares then shareholders would be diluted by this percentage amount.

The Board will review the operation of the Share Rights Plan from time to time and consider whether it is in the Company’s interest to make further grants of share rights.

Shareholder approval sought
Shareholder approval is being sought to issue share rights under the Share Rights Plan to the Managing Director and Chief Executive Officer of the Company, Mr Gradon. Mr Gradon’s participation has been determined by criteria applying to employees generally under the Share Rights Plan. Mr Gradon is the only Director eligible to participate in new grants under the Share Rights Plan. There is no loan proposed in relation to the proposed issue of share rights under the Share Rights Plan to Mr Gradon.

If approved, the share rights will be issued to Mr Gradon by 23 January 2017, which is within 5 months of the Annual Shareholders’ Meeting. The Company intends to issue share rights to selected executives, managers and other employees of the Company and its subsidiaries on or about the same date.

As at 31 March 2016, Mr Gradon held 83,500 share rights under the Share Rights Plan and Michael Daniell held 110,000 share rights under the Share Rights Plan, which were granted to Mr Daniell in his previous capacity as Chief Executive Officer of the Company. No other Director nor any associate of a Director has received share rights granted under the Share Rights Plan (or any predecessor plan).

For the voting exclusions applicable to this resolution, please refer to pages 3 and 4 of this Notice of Meeting. If shareholder approval to issue share rights under the Share Rights Plan to Mr Gradon is not obtained, the Board will investigate alternative long-term variable remuneration arrangements to form part of Mr Gradon’s overall remuneration package.

Key Terms of the Share Rights Plan
The key terms of the Share Rights Plan are:

• No amount is payable by a participant for the grant of share rights.
• One share right gives the participant the potential to exercise that share right for one ordinary share in the Company at no cost.
• Whether (and how many) share rights become exercisable will depend on the Company’s gross total shareholder return (TSR) performance compared to the performance of the Dow Jones
US Select Medical Equipment Total Return Index (DJSMQDT) in New Zealand dollars over the same period (the Index return).

- The Company’s TSR will be calculated and compared against the Index return at the end of the following performance periods:
  - from the date of the grant of the share rights (the Grant Date) to the third anniversary of that date (the First Performance Period);
  - from the Grant Date to the fourth anniversary of that date (the Second Performance Period);
  - from the Grant Date to the fifth anniversary of that date (the Final Performance Period); and
  - if a person or group of persons acting in concert acquires 50% or more of the shares on issue prior to the fifth anniversary of the Grant Date (a Change of Control), from the Grant Date to the date on which that person or group of persons acquires at least 50% of the shares on issue (the Takeover Performance Period).

- Share rights will only become exercisable if the Company’s TSR over the relevant performance period exceeds the Index return over the same period, measured in absolute terms. If at the end of the relevant performance period the Company’s TSR performance over that period exceeds the Index return over the same period by less than 10%, measured in absolute terms, then between 50% and 100% of the share rights held by the participant, as determined on a straight line basis by the Company, become exercisable. If the Company’s TSR over that performance period exceeds the Index return over the same period by 10% or more, measured in absolute terms, then all of the share rights will become exercisable as at the end of the relevant performance period.

- At the end of the First Performance Period, the Company will advise each participant whether any of their share rights are exercisable depending on the above methodology and if they are, the number of share rights which are exercisable. The participant may then choose to exercise any exercisable share rights (in which case any share rights which are not exercised or are not capable of exercise will lapse) or not.

- Exercisable share rights may only be exercised during the 20 business day period from the date that the participant is notified that the share rights have become exercisable following the end of the relevant performance period (the exercise period). The Board has discretion to extend an exercise period or set a new exercise period if the exercise period would otherwise fall outside of a permitted trading period under the Company’s securities trading policy. If the participant chooses not to exercise any exercisable share rights (or no share rights are exercisable because the Company’s TSR over the performance period has not...
exceeded the Index return over the same period), the process is repeated at the end of the Second Performance Period and, if necessary, at the end of the Final Performance Period. The process is also repeated if a Change of Control occurs, at the end of the Takeover Performance Period. At the end of the exercise period in respect of the Final Performance Period, any unexercised share rights and any share rights which are not capable of exercise will lapse.

• Unless otherwise determined by the Board, a participant’s share rights will lapse on the first to occur of the following events:
  • the exercise of any of that participant’s share rights within an exercise period;
  • 5pm on the last day of the exercise period in respect of the Final Performance Period;
  • in the case of share rights held by a participant who ceases to be employed because of serious illness, accident, permanent disablement, redundancy, death or after a person or group of persons acting in concert acquires 50% or more of the shares on issue, in each case after the third anniversary of the date of grant of the share rights, the last date of the exercise period in respect of the next performance period following the date of which the participant ceases to be employed; and
  • in the case of share rights held by a participant who ceases to be employed because of any other reason, the day on which that person ceases to be employed.

• Subject to any applicable Listing Rules, the Board is given discretion to adjust the terms of any share rights to achieve equivalent treatment as between the participants in the Share Rights Plan and the shareholders in the event of a change in the capital structure of the Company.

• The Company may amend the terms of the Share Rights Plan, subject to the consent of any adversely affected participant.

• Share rights are not transferable, other than to certain persons associated with an employee and approved by the Board, and do not participate in dividends or other distributions of the Company. Participants are not entitled to participate in new issues of the underlying securities (such as a rights issue or bonus issue) prior to exercising the share rights.

• Share rights will not be quoted on either the NZX Main Board or the ASX markets. So long as the Company remains listed on the NZX Main Board and/or the ASX markets it is intended that the shares issued on exercise of share rights will be quoted on the NZX Main Board and/or the ASX markets (as applicable).

• Ordinary shares issued or transferred on the exercise of share rights will be fully paid and rank equally with all other
ordinary shares in the Company except for dividends declared or payable in respect of any period prior to the issue of the relevant shares.

- Further information about the Share Rights Plan, including a copy of the documentation giving effect to the plan, is available for review on the Company's website at https://www.fphcare.co.nz/investor/corporate-governance/long-term-incentive-plans/.

EXPLANATORY NOTE 7 - FISHER & PAYKEL HEALTHCARE 2003 SHARE OPTION PLAN – ISSUE OF OPTIONS TO THE MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

Introduction
As described in Explanatory Note 6, the Board intends for the Option Plan and the Share Rights Plan to operate alongside each other.

The Board believes that the issue of a combination of options and share rights broadly in equal value proportions will provide appropriate incentive for participating employees to grow the total shareholder return of the Company. The combination of the Option Plan and the Share Rights Plan will also assist the Company to attract, motivate and retain key employees in an environment where such employees are in high demand both within New Zealand and internationally. Options and share rights will be issued to employees under the Option Plan and Share Rights Plan as a long-term component of remuneration provided to employees in accordance with the Company’s remuneration policy, a summary of which is available on the Company’s website at www.fphcare.co.nz/investor/corporate-governance/corporate-governance-policy.

The Option Plan was established by the Company in 2003 in accordance with the Option Plan rules dated 7 March 2003 and amended on 12 August 2004, 22 November 2006, 22 April 2010, 25 May 2010 and 16 July 2012. Under the latest amendment to the Option Plan, all options will vest after the third anniversary of the grant date provided that the Company’s share price on the NZX Main Board has, at any time on or after the third anniversary of the grant date, exceeded the “Escalated Price” described under the heading “Key Terms of the Option Plan” on page 15.

At last year’s Annual Shareholders’ Meeting, approval was obtained to issue 120,000 options to Michael Daniell (who was the Managing Director and Chief Executive Officer at the time of issue) and it was indicated that up to 1,480,000 options could be issued to other executives, managers and employees. The actual number of options issued to Mr Daniell was 80,000, and 1,226,560 options were issued to other executives, managers and employees.

This year, shareholder approval is being sought for the grant of up
to 120,000 options under the Option Plan to Lewis Gradon, the Managing Director and Chief Executive Officer of the Company. The Company intends to also issue, pursuant to NZX Main Board Listing Rule 7.3.6, up to 1,480,000 options to selected executives, managers and other employees of the Company and its subsidiaries (or a person associated with them) which will be issued within 5 months of the Annual Shareholders’ Meeting. Together with the share rights proposed to be issued under the Share Rights Plan (see Explanatory Note 6), the Company intends to issue no more than an aggregate of 2,300,000 share rights and options to selected executives, managers and other employees, including Mr Gradon, following the Annual Shareholders’ Meeting. This will equate to the issue of share rights and options to acquire shares representing approximately 0.4% of the total ordinary shares on issue; if all of these options and share rights were exercised for shares then shareholders would be diluted by this percentage amount.

The Company’s cost of capital is used as the performance benchmark in determining a participant’s right to exercise options. The Board believes that the cost of capital is an appropriate performance benchmark as it rewards employees when the Company has outperformed its cost of equity and shareholders have experienced positive returns, and it achieves close alignment of employee’s long term variable remuneration to shareholder returns.

As with previous option plans, the Board will regularly review the operation of the Option Plan and consider whether it is in the Company’s interest to make further grants of options.

**Shareholder approval sought**

Shareholder approval is being sought to issue options under the Option Plan to the Managing Director and Chief Executive Officer of the Company, Lewis Gradon. Mr Gradon’s participation has been determined by criteria applying to employees generally under the Option Plan.

If approved, the options will be issued to Mr Gradon by 23 January 2017, which is within 5 months of the Annual Shareholders’ Meeting. The Company intends to issue options to selected executives, managers and other employees of the Company and its subsidiaries on or about the same date.

Mr Gradon is the only Director eligible to participate in new grants under the Option Plan. There is no loan proposed in relation to the proposed issue of options under the Option Plan to Mr Gradon.

As at 31 March 2016, Mr Gradon held 500,000 options under the Options Plan and Michael Daniell held 630,000 options under the Options Plan, which were granted to Mr Daniell in his previous capacity as Chief Executive Officer of the Company. No other Director nor any associate of a Director has received options granted under the Options Plan (or any predecessor plan).
For the voting exclusions applicable to this resolution, please refer to page 3 and 4 of this Notice of Meeting. If shareholder approval to issue options under the Option Plan to Mr Gradon is not obtained, the Board will investigate alternative long-term variable remuneration arrangements to form part of Mr Gradon’s overall remuneration package.

**Key Terms of the Option Plan**

The key terms of the Option Plan are:

- No amount is payable for the grant of options.
- One option gives the participant the right to subscribe at the exercise price for one ordinary share in the Company subject to meeting the following exercise conditions:
  - the options granted under the Option Plan to a participant on a particular grant date may only be exercised at any time between the third anniversary of the grant date and the fifth anniversary of the grant date; and
  - the Company’s share price on the NZX Main Board has, at any time on or after the third anniversary of the grant date, exceeded the “Escalated Price” (described below).
- Unless otherwise determined by the Board:
  - if the participant ceases employment with the Company due to serious illness, accident, permanent disablement, redundancy or after a person or group of persons acting in concert acquires 50% or more of the shares on issue, the participant will have one month to exercise all outstanding options;
  - in the event of the participant’s death, the participant’s executor will have three months to exercise all outstanding options; and
  - on termination of employment for any other reason all outstanding options held by the participant will expire.
- The exercise price of the options to be granted under the Option Plan following the Annual Shareholders’ Meeting will be the volume weighted average price for a share on the NZX Main Board for the five business days prior to the grant date for the options.
- The Escalated Price is determined as follows:
  - As at each anniversary of the grant date up to and including the third anniversary of the grant date for an option, a “base price” will be calculated by:
    - increasing the last calculated base price (which as at the first anniversary of the grant date will be the exercise price of the option) by a percentage amount determined by the Board to represent the Company’s cost of capital; and
    - reducing the resulting figure by the amount of any
dividend paid by the Company in the 12 month period immediately preceding that anniversary.

- The Escalated Price will be the base price determined as at the third anniversary of the grant date in accordance with the above.

- Subject to any applicable Listing Rules, the Board is given discretion to adjust the terms of any options (including the exercise price) to achieve equivalent treatment as between the participants in the Option Plan and the shareholders in the event of a change in the capital structure of the Company.

- The Company may amend the terms of the Option Plan, subject to the consent of any adversely affected participant.

- Options are not transferable, other than to certain persons associated with an employee, and do not participate in dividends or other distributions of the Company. Participants are not entitled to participate in new issues of the underlying securities (such as a rights issue or bonus issue) prior to exercising the options.

- Options will not be quoted on either the NZX Main Board or the ASX markets. So long as the Company remains listed on the NZX Main Board and/or the ASX markets it is intended that the shares issued on exercise of options will be quoted on the NZX Main Board and/or the ASX markets (as applicable).

- Ordinary shares issued or transferred on the exercise of options will be fully paid and rank equally with all other ordinary shares in the Company except for dividends declared or payable in respect of any period prior to the issue of the relevant shares.

- The Cancellation Offer facility approved by shareholders at the 2004 Annual Shareholders’ Meeting (which allows optionholders to cancel vested options in consideration for shares of a value equal to the gain that the optionholders would receive if they exercised their options) applies to the options granted under the Option Plan.

- Further information about the Option Plan, including a copy of the documentation giving effect to the plan, is available for review on the Company’s website at https://www.fphcare.co.nz/investor/corporate-governance/long-term-incentive-plans.